Prestige BioPharma Limited

KSE 950210.KS

Prestige BioPharma Limited Gross Profit Margin for the year ending June 30, 2024: 100.00%

Prestige BioPharma Limited Gross Profit Margin is 100.00% for the year ending June 30, 2024, a 101.41% change year over year. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.

Prestige BioPharma Limited Gross Profit Margin for the year ending June 30, 2023 was -7,103.88%.

Key data

Date	Gross Profit Margin	Operating Income Margin	EBT Margin	Net Income Margin

KSE: 950210.KS

Prestige BioPharma Limited

CEO	Ms. So-Yeon Park
IPO Date	Feb. 9, 2021
Location	Singapore
Headquarters	21 Biopolis Road
Employees	66
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Prestige BioPharma Limited, a biopharmaceutical company, engages in the research, development, and marketing of biosimilars and new antibody therapeutics in the Asia Pacific. The company primarily engages in the development of new and similar antibody drugs for solid tumor, pancreatic cancer, breast cancer, gastric cancer, and arthritis. It is also developing vaccines for COVID-19 virus. The company was incorporated in 2015 and is headquartered in Singapore.

Key trends

Past 5 years